Biotek-snakken — September 2024
-
Board member purchases shares in Acarix
I dag kl. 14:02 ∙ MFN
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Dr. Tony Daz, Board member of Acarix, purchased 2,000,600 shares in the company between September 9 and September 11 at an average price of USD 0.031 per share. His total ownership amounts to 2,000,600 shares.
"I have great faith in the company and its product. The Acarix system is a disruptive technology to rapidly rule out CAD in a cost-effective way and -
Godmorgen
-
FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy https://proinvestor.com/investornyt/1213082/fda-oks-genentechs-tecentriq-hybreza-as-first-amp-only-subcutaneous-anti-pd-l1-cancer-immunotherapy
-
Immuneering Reports Positive Initial Data For IMM-1-104 In Phase 2a Pancreatic Cancer Trial;stock Up https://proinvestor.com/investornyt/1213091/immuneering-reports-positive-initial-data-for-imm-1-104-in-phase-2a-pancreatic-cancer-trialstock-up
-
Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down https://proinvestor.com/investornyt/1213096/cidara-eliminates-30-of-workforce-to-prioritize-clinical-development-of-cd388-stock-down
-
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
-
Der er gange i flere biotek i aften pga ESMO https://finance.yahoo.com/news/esmo-moderna-mrna-solid-tumour-101238212.html
-
-
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC https://proinvestor.com/investornyt/1213639/pfizers-braftovi-mektovi-delivers-long-term-benefits-in-braf-v600e-mutant-nsclc
-
Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipelinehttps://proinvestor.com/investornyt/1213636/bicycle-therapeutics-reveals-updated-clinical-results-across-oncology-pipeline
-
Sutro Announces Updated Data From Phase 1b Study Of Luvelta Combination In Epithelial Ovarian Cancer https://proinvestor.com/investornyt/1213654/sutro-announces-updated-data-from-phase-1b-study-of-luvelta-combination-in-epithelial-ovarian-cancer
-
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? https://proinvestor.com/investornyt/1213644/up-more-than-500-in-2024-can-instil-bio-keep-rocketing-higher
-
Penser Access & Future by Carnegie: Ascelia Pharma: Kassan fylld
Penser Access & Future by Carnegie: Ascelia Pharma: Kassan fylld
Fulltecknad företrädesemission Ascelia meddelade nyligen att bolagets företrädesmission blivit fulltecknad och bolaget kommer att tillföras en bruttolikvid om 105 mkr. Företrädesemissionen v...
MFN (mfn.se)
Aktiekurs 2,1 kr - Motiverat värde 5,0 - 7,0 kr.
-
Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study https://proinvestor.com/investornyt/1213975/johnson-amp-johnson-reports-promising-interim-data-from-phase-2-sunrise-4-study
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind